ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
SEK 20.6
(-4.63%)
SEK 20.6
(-4.63%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.05 Million SEK | 38.62% |
| 2022 | 5.08 Million SEK | -58.43% |
| 2021 | 12.23 Million SEK | 132.63% |
| 2020 | 5.25 Million SEK | -61.97% |
| 2019 | 13.82 Million SEK | 55.94% |
| 2018 | 8.86 Million SEK | -9.46% |
| 2017 | 9.79 Million SEK | 110.55% |
| 2016 | 4.65 Million SEK | 0.0% |
| 2015 | - SEK | -100.0% |
| 2014 | 6.61 Million SEK | -0.75% |
| 2013 | 6.66 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 923 Thousand SEK | -16.77% |
| 2024 Q2 | 1.03 Million SEK | 11.81% |
| 2023 Q2 | 1.92 Million SEK | -25.14% |
| 2023 Q4 | 1.1 Million SEK | -23.73% |
| 2023 FY | 7.05 Million SEK | 38.62% |
| 2023 Q3 | 1.45 Million SEK | -24.31% |
| 2023 Q1 | 2.56 Million SEK | 163.99% |
| 2022 Q3 | 833 Thousand SEK | -33.25% |
| 2022 FY | 5.08 Million SEK | -58.43% |
| 2022 Q4 | 972 Thousand SEK | 16.69% |
| 2022 Q2 | 1.24 Million SEK | -38.61% |
| 2022 Q1 | 2.03 Million SEK | -40.17% |
| 2021 Q3 | 2.54 Million SEK | -44.42% |
| 2021 Q1 | 1.7 Million SEK | 136.05% |
| 2021 Q2 | 4.58 Million SEK | 169.01% |
| 2021 FY | 12.23 Million SEK | 132.63% |
| 2021 Q4 | 3.39 Million SEK | 33.36% |
| 2020 Q2 | 4.01 Million SEK | 41.96% |
| 2020 Q1 | 2.82 Million SEK | -21.66% |
| 2020 Q3 | 3.14 Million SEK | -21.79% |
| 2020 FY | 5.25 Million SEK | -61.97% |
| 2020 Q4 | -4.72 Million SEK | -250.49% |
| 2019 Q4 | 3.61 Million SEK | 14.34% |
| 2019 Q1 | 2.72 Million SEK | 89.62% |
| 2019 FY | 13.82 Million SEK | 55.94% |
| 2019 Q3 | 3.15 Million SEK | -27.22% |
| 2019 Q2 | 4.33 Million SEK | 59.46% |
| 2018 Q1 | 2.27 Million SEK | 24.96% |
| 2018 FY | 8.86 Million SEK | -9.46% |
| 2018 Q3 | 2.17 Million SEK | -27.13% |
| 2018 Q2 | 2.98 Million SEK | 30.9% |
| 2018 Q4 | 1.43 Million SEK | -33.96% |
| 2017 Q1 | 3.61 Million SEK | 49.77% |
| 2017 Q3 | 2.04 Million SEK | -11.34% |
| 2017 Q4 | 1.82 Million SEK | -10.99% |
| 2017 FY | 9.79 Million SEK | 110.55% |
| 2017 Q2 | 2.31 Million SEK | -36.08% |
| 2016 Q4 | 2.41 Million SEK | 69.81% |
| 2016 Q2 | 818 Thousand SEK | -82.42% |
| 2016 FY | 4.65 Million SEK | 0.0% |
| 2016 Q1 | 4.65 Million SEK | 0.0% |
| 2016 Q3 | 1.42 Million SEK | 73.72% |
| 2015 FY | - SEK | -100.0% |
| 2014 FY | 6.61 Million SEK | -0.75% |
| 2013 FY | 6.66 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 87.867% |
| Ziccum AB (publ) | 3.74 Million SEK | -88.151% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 98.856% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 86.035% |
| Mendus AB (publ) | 28.48 Million SEK | 75.252% |
| Genovis AB (publ.) | 158.23 Million SEK | 95.545% |
| Intervacc AB (publ) | 8.01 Million SEK | 12.04% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -61.18% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 95.864% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 83.939% |
| Aptahem AB (publ) | 2.63 Million SEK | -167.995% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -581.159% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -9055.844% |
| Fluicell AB (publ) | 3.33 Million SEK | -111.204% |
| Saniona AB (publ) | 16.84 Million SEK | 58.135% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 57.031% |
| Biovica International AB (publ) | 7.29 Million SEK | 3.292% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -486.035% |
| AcouSort AB (publ) | 10.55 Million SEK | 33.182% |
| Xintela AB (publ) | 78 Thousand SEK | -8938.462% |
| Abliva AB (publ) | 137 Thousand SEK | -5045.985% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 87.76% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -250.05% |
| OncoZenge AB (publ) | 3000.00 SEK | -234900.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -4448.387% |
| CombiGene AB (publ) | 5.54 Million SEK | -27.162% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.416% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.589% |
| Corline Biomedical AB | 25.03 Million SEK | 71.834% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -24.163% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -877.809% |
| I-Tech AB | 120.86 Million SEK | 94.167% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 94.742% |
| Cyxone AB (publ) | 5.14 Million SEK | -36.946% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 33.894% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 37.222% |
| Nanologica AB (publ) | 1.44 Million SEK | -388.565% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -13201.887% |
| BioInvent International AB (publ) | 71.46 Million SEK | 90.134% |
| Alzinova AB (publ) | 270 Thousand SEK | -2511.111% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 79.983% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -381.88% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -149.823% |
| Simris Alg AB (publ) | 4.35 Million SEK | -61.92% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -5323.077% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 97.047% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -30552.174% |